Clinical Practice Guideline

Treating Tobacco Use and Dependence

Guideline Panel

Michael C. Fiore, MD (Panel Chair)
William C. Bailey, MD
Stuart J. Cohen, EdD
Sally Faith Dorfman, MD, MSHSA
Michael G. Goldstein, MD
Ellen R. Gritz, PhD
Richard B. Heyman, MD
Carlos Roberto Jaén, MD, PhD
Thomas E. Kottke, MD, MSPH
Harry A. Lando, PhD
Robert E. Mecklenburg, DDS, MPH
Patricia Dolan Mullen, DrPH
Louise M. Nett, RN, RRT
Lawrence Robinson, MD, MPH
Maxine L. Stitzer, PhD
Anthony C. Tommasello, MS
Louise Villejo, MPH, CHES
Mary Ellen Wewers, PhD, RN

Guideline Staff

Timothy Baker, PhD
Brion J. Fox, JD
Victor Hasselblad, PhD

U.S. Department of Health and Human Services
Public Health Service

June 2000
Guideline Development and Use

*Treating Tobacco Use and Dependence*, a Public Health Service-sponsored Clinical Practice Guideline, is the result of an extraordinary partnership among Federal Government and nonprofit organizations comprised of the Agency for Healthcare Research and Quality; Centers for Disease Control and Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; Robert Wood Johnson Foundation; and University of Wisconsin Medical School’s Center for Tobacco Research and Intervention. Each member of this consortium is dedicated to improving the Nation’s public health, and their participation in this collaboration clearly demonstrates a strong commitment to tobacco cessation.

This guideline is an updated version of the 1996 Smoking Cessation Clinical Practice Guideline No. 18. It is the product of a private-sector panel of experts, consortium representatives, and staff. The update was written to include new, effective clinical treatments for tobacco dependence that have become available since the original guideline was developed. *Treating Tobacco Use and Dependence* will make an important contribution to the quality of care in the United States and the health of the American people.

The panel employed an explicit, science-based methodology and expert clinical judgment to develop recommendations on the treatment of tobacco use and dependence. Extensive literature searches were conducted, and critical reviews and syntheses were used to evaluate empirical evidence and significant outcomes. Peer and field reviews were undertaken to evaluate the validity, reliability, and utility of the guideline in clinical practice. The panel’s recommendations are primarily based on published, evidence-based research. When the evidence was incomplete or inconsistent in a particular area, the recommendations reflect the professional judgment of panel members and consultants.

The recommendations herein may not be appropriate for use in all circumstances. Decisions to adopt any particular recommendation must be made by clinicians in light of available resources and circumstances presented by individual patients.

This Public Health Service-sponsored Clinical Practice Guideline gives hope to the 7 out of 10 smokers who try to quit each year. I urge every clinician, health plan, and health care institution to make treating tobacco dependence a top priority. Please ask your patients two key questions: “Do you smoke?” “Do you want to quit?” followed by use of the recommendations in this guideline.

David Satcher, MD, PhD
*U.S. Surgeon General*
*Assistant Secretary for Health*
Abstract

_Treating Tobacco Use and Dependence_, a Public Health Service-sponsored Clinical Practice Guideline, is a product of the Tobacco Use and Dependence Guideline Panel (“the panel”), consortium representatives, consultants, and staff. These 30 individuals were charged with the responsibility of identifying effective, experimentally validated tobacco dependence treatments and practices. The updated guideline was sponsored by a consortium of seven Federal Government and nonprofit organizations: the Agency for Healthcare Research and Quality (AHRQ); Centers for Disease Control and Prevention (CDC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute on Drug Abuse (NIDA); Robert Wood Johnson Foundation (RWJF); and University of Wisconsin Medical School’s Center for Tobacco Research and Intervention (CTRI). This guideline is an updated version of the 1996 _Smoking Cessation Clinical Practice Guideline No. 18_ that was sponsored by the Agency for Health Care Policy and Research (now the AHRQ), U.S. Department of Health and Human Services. The original guideline reflected the extant scientific research literature published between 1975 and 1994.

The updated guideline was written because new, effective clinical treatments for tobacco dependence have been identified since 1994. The accelerating pace of tobacco research that prompted the update is reflected in the fact that 3,000 articles on tobacco were identified as published between 1975 and 1994, contributing to the original guideline. Another 3,000 were published between 1995 and 1999 and contributed to the updated guideline. These 6,000 articles were screened and reviewed to identify a much smaller group of articles that served as the basis for guideline data analyses and panel opinion.

This guideline contains strategies and recommendations designed to assist clinicians; tobacco dependence treatment specialists; and health care administrators, insurers, and purchasers in delivering and supporting effective treatments for tobacco use and dependence. The recommendations were made as a result of a systematic review and analysis of the extant scientific literature, using meta-analysis as the primary analytic technique. The strength of evidence that served as the basis for each recommendation is clearly indicated in the guideline. A draft of the guideline was peer-reviewed prior to publication, and the comments of 70 external reviewers were incorporated into the final document. The key recommendations of the updated guideline, _Treating Tobacco Use and Dependence_, based on the literature review and expert panel opinion, are as follows:

1. Tobacco dependence is a chronic condition that often requires repeated intervention. However, effective treatments exist that can produce long-term or even permanent abstinence.

2. Because effective tobacco dependence treatments are available, every patient who uses tobacco should be offered at least one of these treatments:
Patients *willing* to try to quit tobacco use should be provided with treatments identified as effective in this guideline.

Patients *unwilling* to try to quit tobacco use should be provided with a brief intervention designed to increase their motivation to quit.

3. It is essential that clinicians and health care delivery systems (including administrators, insurers, and purchasers) institutionalize the consistent identification, documentation, and treatment of every tobacco user seen in a health care setting.

4. Brief tobacco dependence treatment is effective, and every patient who uses tobacco should be offered at least brief treatment.

5. There is a strong dose-response relation between the intensity of tobacco dependence counseling and its effectiveness. Treatments involving person-to-person contact (via individual, group, or proactive telephone counseling) are consistently effective, and their effectiveness increases with treatment intensity (e.g., minutes of contact).

6. Three types of counseling and behavioral therapies were found to be especially effective and should be used with all patients attempting tobacco cessation:
   - Provision of practical counseling (problemsolving/skills training);
   - Provision of social support as part of treatment (intra-treatment social support); and
   - Help in securing social support outside of treatment (extra-treatment social support).

7. Numerous effective pharmacotherapies for smoking cessation now exist. Except in the presence of contraindications, these should be used with all patients attempting to quit smoking.
   - Five *first-line* pharmacotherapies were identified that reliably increase long-term smoking abstinence rates:
     - Bupropion SR
     - Nicotine gum
     - Nicotine inhaler
     - Nicotine nasal spray
     - Nicotine patch
   - Two *second-line* pharmacotherapies were identified as efficacious and may be considered by clinicians if first-line pharmacotherapies are not effective:
     - Clonidine
     - Nortriptyline
Over-the-counter nicotine patches are effective relative to placebo, and their use should be encouraged.

8. Tobacco dependence treatments are both clinically effective and cost-effective relative to other medical and disease prevention interventions. As such, insurers and purchasers should ensure that:

- All insurance plans include as a reimbursed benefit the counseling and pharmacotherapeutic treatments identified as effective in this guideline; and
- Clinicians are reimbursed for providing tobacco dependence treatment just as they are reimbursed for treating other chronic conditions.

The updated guideline is divided into eight chapters that provide an overview including methods (Chapter 1), information on the assessment of tobacco use (Chapter 2), brief clinical interventions, both for patients willing and unwilling to make a quit attempt at this time (Chapter 3), intensive clinical interventions (Chapter 4), systems interventions for health care administrators, insurers, and purchasers (Chapter 5), the scientific evidence supporting the guideline recommendations (Chapter 6), and special populations and topics (Chapters 7 and 8).

A comparison of the findings of the updated guideline with the original guideline reveals the considerable progress made in tobacco research over the brief period separating these two publications. Tobacco dependence is now increasingly recognized as a chronic disease, one that typically requires ongoing assessment and repeated intervention. In addition, the updated guideline offers the clinician many more efficacious treatment strategies than were identified in the original guideline. There are now seven different efficacious agents in the smoking cessation pharmacopoeia, allowing the clinician and patient many different medication options. In addition, recent evidence has identified new, efficacious counseling strategies. In particular, proactive telephone counseling is efficacious, as is counseling that helps smokers attain social support outside of the treatment context. The updated guideline also reveals greater evidence of the strong dose-response relation between counseling intensity and the likelihood of long-term abstinence from tobacco. Indeed, the data are compelling that pharmacologic and counseling treatment each independently boost cessation success; these data suggest that optimal cessation outcomes may require the combined use of both counseling and pharmacotherapy.

Finally, there is increasing evidence that the success of any tobacco dependence treatment strategy or effort cannot be divorced from the health care system in which it is embedded. Data strongly indicate that effective tobacco interventions require coordinated interventions. Just as the clinician must intervene with his or her patient, so must the health care administrator, insurer, and purchaser foster and support tobacco intervention as an integral element of health care delivery. Health care administrators and insurers should ensure that clinicians have the training and support, and receive the reimbursement necessary to achieve consistent, effective intervention with tobacco users.
One important conclusion of this guideline is that the most effective way to move clinicians to intervene is to provide them with information regarding multiple efficacious treatment options and to ensure that they have ample institutional support to use these options. Indeed, in this guideline, the panel encourages a culture of health care in which failure to treat tobacco use—the chief cause of preventable disease and death—constitutes an inappropriate standard of care.

This document is in the public domain and may be used and reprinted without special permission. The Public Health Service appreciates citation as to source, and the suggested format is provided below:

Acknowledgments

This guideline would not have been possible without the collaborative efforts of many individuals and organizations. Each made significant contributions throughout the process of updating this guideline. While too numerous to list here, the Contributors section of this publication provides a listing of support staff, individual peer reviewers, and others. There are, however, some individuals and organizations that deserve special mention.

The panel wishes to acknowledge the support and guidance provided by the consortium partners in general and their dedicated, hard working representatives in particular. Specifically, the panel gratefully acknowledges the extraordinarily supportive efforts and substantial contribution throughout the project of Ernestine W. Murray, RN, MAS, Panel Project Officer, Center for Practice and Technology Assessment, Agency for Healthcare Research and Quality (AHRQ). Additionally, we would like to recognize the outstanding contributions of other AHRQ staff: Douglas B. Kamerow, MD, MPH, Director, Center for Practice and Technology Assessment; Harriett V. Bennett, Public Affairs and Marketing Specialist, Office of Health Care Information; and Sandra Katz Cummings, Managing Editor, Office of Health Care Information. The panel particularly wishes to thank Glen D. Morgan, PhD, at the National Cancer Institute; Corinne Husten, MD, MPH, and Cathy Melvin, PhD, MPH, Office on Smoking and Health at the Centers for Disease Control and Prevention; Glen Bennett, MPH, at the National Heart, Lung, and Blood Institute; Stephen J. Heishman, PhD, at the National Institute on Drug Abuse; C. Tracy Orleans, PhD, at the Robert Wood Johnson Foundation; and Douglas Jorenby, PhD, at the Center for Tobacco Research and Intervention, University of Wisconsin Medical School.

The panel also wishes to thank Marc Manley, MD, MPH; John Mullahy, PhD; David Schriger, MD, MPH; and David Wetter, PhD, consultants on the project, for their insight and intellectual contributions.

Finally, the panel extends its gratitude and appreciation to the staff members at the University of Wisconsin Medical School’s Center for Tobacco Research and Intervention for their tireless efforts in bringing this project to completion. In particular, the panel acknowledges and thanks Bridget Whisler, Project Manager; and Megan Piper, MA, and Sam Welsch, Senior Research Associates.
Contents

Executive Summary ............................................................................................................. 1

1. Overview and Methods ................................................................................................. 7
   Introduction ..................................................................................................................... 7
   Rationale for Initial Guideline Development and Year 2000 Update ......................... 8
   Tobacco Dependence as a Chronic Disease ............................................................... 9
   Guideline Development Methodology ........................................................................ 10
      Introduction ............................................................................................................ 10
      Topics Included in the Guideline ........................................................................ 11
      Guideline Development Process .......................................................................... 11
      Selection of Evidence ......................................................................................... 11
      Literature Review and Inclusion Criteria .......................................................... 12
      Preparation of Evidence Tables ........................................................................... 13
      Outcome Data ....................................................................................................... 14
      Meta-Analytic Techniques .................................................................................. 15
      How To Read the Data Tables ......................................................................... 17
      Strength of Evidence ...................................................................................... 19
      Caveats Regarding Recommendations .......................................................... 19
      External Review of the Guideline .............................................................. 20
   Guideline Products .................................................................................................... 20
   Organization of the Guideline Update ........................................................................... 21

2. Assessment of Tobacco Use ......................................................................................... 23

3. Brief Clinical Interventions ......................................................................................... 25
   Background ............................................................................................................. 25
   A. For the Patient Willing To Quit ........................................................................ 25
      Brief Strategies: Helping the Patient Willing To Quit ...................................... 28
   B. For the Patient Unwilling To Quit .................................................................... 31
      Promoting the Motivation To Quit ................................................................ 31
   C. For the Patient Who Has Recently Quit ........................................................... 33
      Preventing Relapse ......................................................................................... 33
      Brief Strategies: Preventing Relapse to Tobacco Use ...................................... 34

4. Intensive Clinical Interventions ................................................................................... 37
   Background ............................................................................................................. 37
   Strategies for Intensive Tobacco Dependence Intervention ..................................... 38

5. Systems Interventions: Relevance to Health Care Administrators, Insurers, and Purchasers ............................................................................................................. 41
   Background ........................................................................................................... 41
   Cost-Effectiveness of Smoking Cessation Interventions ...................................... 42
Recommendations for Health Care Administrators, Insurers, and Purchasers ........................................................................................................... 42
Strategies for Health Care Administrators, Insurers, and Purchasers ....... 44

6. Evidence .................................................................................................... 49
   Background .................................................................................................. 49
   A. Screening and Assessment ..................................................................... 52
      Screen for Tobacco Use ......................................................................... 52
      Future Research ...................................................................................... 53
      Specialized Assessment .......................................................................... 54
      Future Research ...................................................................................... 56
   B. Treatment Structure and Intensity ........................................................... 56
      Advice To Quit Smoking ......................................................................... 56
      Future Research ...................................................................................... 57
      Intensity of Clinical Interventions ............................................................ 57
      Future Research ...................................................................................... 59
      Type of Clinician ..................................................................................... 60
      Future Research ...................................................................................... 61
      Formats of Psychosocial Treatments .......................................................... 62
      Future Research ...................................................................................... 64
      Followup Assessment and Procedures ....................................................... 64
      Future Research ...................................................................................... 65
   C. Treatment Elements ................................................................................ 65
      Types of Counseling and Behavioral Therapies ........................................ 65
      Future Research ...................................................................................... 70
      Alternative Treatment Models for the Treatment of Tobacco Dependence—Stepped Care and Individual Tailoring ........................................ 70
      Pharmacotherapy ..................................................................................... 71

Recommendations Regarding Specific Pharmacotherapies:
   First-Line Medications ............................................................................. 72
      Bupropion SR (Sustained Release Bupropion) ........................................ 72
      Nicotine Gum .......................................................................................... 73
      Nicotine Inhaler ....................................................................................... 73
      Nicotine Nasal Spray .............................................................................. 74
      Nicotine Patch ......................................................................................... 74
   Second-Line Medications ........................................................................ 75
      Clonidine .................................................................................................. 75
      Nortriptyline ............................................................................................ 76
      Combination Nicotine Replacement Therapy ........................................... 77

Pharmacotherapies Not Recommended by the Guideline Panel ............... 78
   Antidepressants Other Than Bupropion SR and Nortriptyline ................. 78
   Anxiolytics/Benzodiazepines/Beta-Blockers ............................................. 78
   Silver Acetate .............................................................................................. 79
Contents

Mecamylamine ........................................................................................ 79
Pharmacotherapy for Treating Tobacco Dependence:
  Issues Relevant to Use ...................................................................... 79
  Overcoming Clinician Reluctance to Use Pharmacotherapy ............ 79
  Extended Use of Pharmacotherapy ................................................. 80
  Recommending Specific Pharmacotherapy for Specific
  Patient Subgroups ......................................................................... 80
  Use of Nicotine Replacement Therapy in Cardiovascular Patients .... 81
  Future Research ........................................................................... 81
  Over-the-Counter Pharmacotherapeutic Interventions ................... 84
  Future Research ........................................................................... 89

7. Special Populations ......................................................................... 91
  Background ..................................................................................... 91
  Gender ............................................................................................. 91
    Future Research ........................................................................... 92
  Pregnancy ....................................................................................... 92
    Future Research ........................................................................... 96
  Racial and Ethnic Minorities .......................................................... 96
    Future Research ........................................................................... 97
  Hospitalized Smokers .................................................................... 98
    Future Research ........................................................................... 99
  Smokers With Psychiatric Comorbidity and/or Chemical Dependency .. 99
    Future Research ........................................................................... 101
  Children and Adolescents ............................................................... 101
    Tobacco Use Treatments in Children and Adolescents ............... 102
    Future Research ........................................................................... 103
  Older Smokers ............................................................................... 103
    Future Research ........................................................................... 104

8. Special Topics .............................................................................. 105
  Background ..................................................................................... 105
  Weight Gain After Smoking Cessation .......................................... 105
    Recommendations to Clinicians When Addressing Weight Gain .... 106
    Future Research ........................................................................... 107
  Noncigarette Tobacco Products .................................................... 108
    Future Research ........................................................................... 109
  Clinician Training .......................................................................... 109
    Future Research ........................................................................... 110
  Economic Aspects of Tobacco Dependence Treatments and Health
    Systems Interventions ................................................................ 111
    Future Research ........................................................................... 112
  Alternative Treatment Goals: Harm Reduction ............................ 113

References ....................................................................................... 115
19. Meta-analysis: Efficacy of and estimated abstinence rates for number of types of self-help ................................................................. 64
20. Meta-analysis: Efficacy of and estimated abstinence rates for various types of counseling and behavioral therapies .............................. 66
21. Common elements of practical counseling (problem-solving/skills training) .................................................................................. 68
22. Common elements of intra-treatment supportive interventions .......... 69
23. Common elements of extra-treatment supportive interventions .......... 69
24. Meta-analysis: Efficacy of and estimated abstinence rates for acupuncture ................................................................................... 70
25. Meta-analysis: Efficacy of and estimated abstinence rates for bupropion SR .................................................................................... 72
26. Meta-analysis: Efficacy of and estimated abstinence rates for 2 mg nicotine gum ........................................................................... 73
27. Meta-analysis: Efficacy of and estimated abstinence rates for nicotine inhaler .................................................................................. 74
28. Meta-analysis: Efficacy of and estimated abstinence rates for nicotine nasal spray ................................................................. 74
29. Meta-analysis: Efficacy of and estimated abstinence rates for the nicotine patch ................................................................................ 75
30. Meta-analysis: Efficacy of and estimated abstinence rates for clonidine .................................................................................... 75
31. Meta-analysis: Efficacy of and estimated abstinence rates for nortriptyline .................................................................................... 76
32. Meta-analysis: Efficacy of and estimated abstinence rates for combination NRT ................................................................. 77
33. Suggestions for the clinical use of bupropion SR ................................ 82
34. Suggestions for the clinical use of nicotine gum ................................... 83
35. Suggestions for the clinical use of the nicotine inhaler ......................... 85
36. Suggestions for the clinical use of the nicotine nasal spray .................. 86
37. Suggestions for the clinical use of the nicotine patch ........................... 87
38. Suggestions for the clinical use of clonidine ......................................... 88
39. Suggestions for the clinical use of nortriptyline .................................... 90
40. Meta-analysis: Efficacy of and estimated abstinence rates for over-the-counter nicotine patch therapy ................................................. 90
41. Meta-analysis: Efficacy of and estimated abstinence rates for augmented interventions with pregnant smokers ............................ 93
42. Examples of effective interventions with pregnant patients .................. 94
43. Clinical practice when assisting a pregnant patient in smoking cessation .................................................................................. 95
44. Meta-analysis: Efficacy of and estimated abstinence rates for augmented interventions with hospitalized smokers ....................... 98
45. Suggested interventions for hospitalized patients ............................... 99
46. Clinician statements to help a patient prepare for, and cope with, postcessation weight gain .............................................................. 107
Strategies

Brief Strategy A1. Ask—systematically identify all tobacco users at every visit ........................................................................................................ 28

Brief Strategy A2. Advise—strongly urge all tobacco users to quit .................. 28

Brief Strategy A3. Assess—determine willingness to make a quit attempt ...... 29

Brief Strategy A4. Assist—aid the patient in quitting ........................................ 29

Brief Strategy A5. Arrange—schedule followup contact .................................. 31

Brief Strategy B. Enhancing motivation to quit tobacco—the “5 R’s” .......... 32

Brief Strategy C1. Components of minimal practice relapse prevention .......... 34

Brief Strategy C2. Components of prescriptive relapse prevention ............... 35

Intensive Strategy. Components of an intensive intervention ....................... 39

Systems Strategy 1. Implement a tobacco-user identification system in every clinic ................................................................................................. 44

Systems Strategy 2. Provide education, resources, and feedback to promote provider intervention ................................................................. 45

Systems Strategy 3. Dedicate staff to provide tobacco dependence treatment and assess the delivery of this treatment in staff performance evaluations ................................................................. 45

Systems Strategy 4. Promote hospital policies that support and provide inpatient tobacco dependence services .............................................. 46

Systems Strategy 5. Include tobacco dependence treatments (both counseling and pharmacotherapy) identified as effective in this guideline, as paid or covered services for all subscribers or members of health insurance packages ........................................ 46

Systems Strategy 6. Reimburse clinicians and specialists for delivery of effective tobacco dependence treatments and include these interventions among the defined duties of clinicians ........................................ 47

Figures

1. Guideline development process ................................................................ 12

2. Model for treatment of tobacco use and dependence ................................ 22

3. Algorithm for treating tobacco use ............................................................ 24